Daytrana Safety Issues Remain, Concern Lessened, Reviewer Says In Reversal
Executive Summary
Safety issues with Shire/Noven's Daytrana methylphenidate patch remain but the agency's concern about them has been lessened, FDA's clinical reviewer said in a reversal of his written evaluation on the approvability of the attention deficit/hyperactivity disorder product